Johnson & Johnson Stock Attracts Major Investors Ahead of Strategic Shift
Published on 03/23/2026 at 07:17 | Redaktion boerse-global.de
Recent regulatory filings with the U.S. Securities and Exchange Commission reveal a notable trend: major institutional investors are significantly increasing their holdings in Johnson & Johnson. The healthcare giant is approaching a historic revenue milestone this year and is reportedly preparing a multi-billion dollar divestiture within its medical technology segment. This strategic pivot is capturing the focused attention of professional money managers.
Strategic Divestiture and Pipeline Progress
The company's strategic refinement is moving forward alongside its financial targets. Industry reports indicate Johnson & Johnson is preparing documentation for the potential sale of its orthopedics unit, DePuy Synthes. A transaction could be valued at more than $20 billion. Capital unlocked from such a move is expected to be redirected toward higher-growth areas within the broader medtech landscape.
Concurrently, the pharmaceutical core business continues to deliver robust growth. The oncology drug Darzalex recently generated a ten percent sales increase within its division. Furthermore, the new immunology treatment, Icotyde, is on the verge of accessing a new multi-billion dollar market following recent regulatory progress toward approval.
Confidence Amidst a Historic Revenue Target
The recent buying activity from firms like Great Oak Capital and AIA Group coincides with a pivotal period for the company. Management has set an operational sales target for 2026 between $99.5 and $100.5 billion. Achieving this would mark the first time the corporation surpasses the $100 billion threshold.
The company's handling of the "TrumpRx" agreement finalized in January is particularly noteworthy. Although the deal mandates lower U.S. drug prices in exchange for tariff exemptions, the executive team appears confident. CFO Joseph Wolk has stated that the company expects to absorb the financial impact, which amounts to several hundred million dollars, and still exceed original analyst profit expectations. This confidence is reflected in the share price, which has gained approximately 15% since the start of the year and is currently trading just over four percent below its 52-week high.
Should investors sell immediately? Or is it worth buying Johnson & Johnson?
Wall Street Analysts Revise Targets Upward
The combination of a solid core business and strategic restructuring has prompted positive reactions from market analysts. Several major institutions have updated their assessments in recent days:
- HSBC: "Buy" rating with a $280 price target
- Goldman Sachs: "Buy" rating with a $265 price target
- Morgan Stanley: "Buy" rating with a $262 price target
With a consensus average price target nearing $237, the market is signaling further upside potential for the shares. The preparations for the orthopedics unit separation and the pursuit of the $100 billion revenue mark now stand as the concrete milestones against which management will be measured in the coming quarters.
Ad
Johnson & Johnson Stock: New Analysis - 23 March
Fresh Johnson & Johnson information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
